Last year the COVID-19 pandemic caused a major upheaval globally.Today we can look back at the past three years and applaud the efforts of the pharma andhealthcare industry to tackle COVID-19 which continues to affect many countries eventoday.
The social and economic impact on people and communities globally hasbeen devastating. In the midst of all the disruption science has provided us withsolutions to combat COVID-19 through diagnostics vaccines drugs and various therapies.Fortunately humanity is winning the battle against COVID-19.
During the year we witnessed worldwide solidarity and co-operationamong pharma companies research scientists doctors regulatory bodies and governments.All concerned are still tackling newer and changing variants of the virus. My sincere pleato you all is to be careful look after yourselves your families your friends andcolleagues and be as disciplined as possible.
The financial year ended 31st March 2022 has been a commendable onefor Cipla. We have been recognised and awarded the 'Company of the Year 2021' by BusinessStandard and our Executive Vice-Chairperson Samina Hamied was conferred with The EconomicTimes 'Businesswoman of the Year' 2021 award. Such recognitions reflect the interest andpassion of all our employees who are dedicated committed and motivated to uphold ourlegacy of 'Caring for Life'.
My earnest hope is to see the progress of Cipla as a major globalhealthcare organisation in the near future. Cipla remains committed to provide access toaffordable quality medicines and services towards overall healthcare. For Cipla patientsare at the core of what we do. We strive to create capacity in our Company across manyfronts - manufacturing quality regulatory commercial and R&D development areas. Welook for the best possible talent - financial commercial and technical to join us in ourpursuit of progress and growth be it in science health corporate responsibility orpatient care.
Our founder Dr K A Hamied started Cipla in 1935 from humblebeginnings committing himself and the Company to India's quest for self-reliance andselfsufficiency in the area of healthcare. From our first manufacturing unit at BombayCentral in 1936 Cipla now has over 40 state-of-the art manufacturing facilities acrossthe globe including India USA China and South Africa. To reiterate Cipla's purpose of'Caring for Life' has been our guiding principle. As we move forward we will remain trueto this legacy.
As always Cipla will follow a compassionate and humanitarian approachto healthcare that goes beyond the pursuit of profit. Access to medicines at affordableprices has been the main objective that has seen the growth of Cipla over the past 86years. In 1997 we set up the Cipla Palliative Care and Training Centre in Pune thatprovides free-of-cost services for terminally ill patients. Till date we have cared forapproximately 20000 patients and this effort will continue in the future. Teachingadvanced nursing is imperative to caring for patients and we will continue to conducttrainings for health care professionals. We believe that palliative care must beintegrated into the treatment protocol early on to improve the quality of life of patientsand caregivers.
Finally I would like to assure all of you that your Company will dothe best possible to contribute towards the health and welfare of our nation. My sinceregratitude to all stakeholders in the Company Directors the Management shareholdershealth care professionals and society for their continuing faith and trust in us. Therecent pandemic has taught us many important lessons among these is our need to focus onnew innovative developments and work in partnership with our colleagues in the industryboth in India and globally. We firmly believe that Cipla will contribute and improve thequality of lives everywhere.
|Warm Regards |
|Y K Hamied |